Navigation Links
Experimental drug improves muscle strength among male cancer patients
Date:6/25/2012

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

The medication, called enobosarm, is the first of a new class of drugs known as selective androgen receptor modulators, which are similar to steroids in their growth-enhancing effects but, potentially, have fewer side effects.

Muscle wasting is a significant problem for many cancer patients due to imbalances in body systems caused by the underlying cancer. In addition, this muscle wasting may be related to low testosterone levels, or hypogonadism, which affects approximately 50 percent of men undergoing treatment for late-stage cancer. Muscle wasting can seriously limit mobility, functioning, and quality of life for affected patients.

In this multi-center drug trial, enobosarm significantly improved physical function among patients with low testosterone, as well as normal hormone levels. Among the low testosterone group, physical function improved by 19 percent, while patients with normal hormone measurements increase their functional ability by 13 percent. At the study's start, 60 percent of patients had subnormal testosterone levels, lost more weight, and suffered greater declines in physical functioning than patients with normal hormone concentrations.

"These data provide evidence that enobosarm may play an important role in the management of cancer-related muscle-wasting even in the setting of low testosterone," said study lead author Adrian Dobs, M.D., M.H.S., professor of medicine and oncology, and vice-chair of the Department of Medicine, Faculty Development at Johns Hopkins University Medical School in Baltimore, MD.

The overall study included 159 cancer patients, of which 65 percent were men. Female participants were post-menopausal, and males were >45 years old. Participants had lost on average about 8 percent of their body weight in the six months preceding the study, and had a body mass index, which is a calculation of weight to height, of <35. Additionally, all patients had received a cancer diagnosis, which included one of the following: non-small-cell lung carcinoma, colorectal cancer, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and breast cancer.

This particular study examined a subset of this population, which comprised 93 male patients. Sixty percent of these men had low testosterone levels at the beginning of the trial. Investigators randomly assigned these participants to receive either 1 or 3 milligrams of oral enobosarm or placebo daily for 16 weeks. Since the trial was double-blinded, neither patients nor researchers knew which group was receiving the study drug versus placebo. At the study's beginning and end, investigators assessed patients' physical functioning using a stair-climbing test.

According to Dobs, this study laid the groundwork for ongoing research examining enobosarm's effects on muscle-wasting specifically among lung-cancer patients.

"Enobosarm has the potential to improve physical performance and increase muscle mass, potentially providing lung-cancer patients with improved strength, or physical function, more independence, increased quality of life, better response to chemotherapy and hopefully longer survival," Dobs said.

Previous findings from the larger study comprising male and female patients have been reported, but these data on the subset of male patients with baseline low testosterone are being presented for the first time.


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
2. Experimental Drug Eases Autistic Behaviors in Mice
3. Experimental Gel May Help Those With Advanced Parkinsons
4. Experimental Pill for Multiple Sclerosis Shows Promise
5. Experimental Chemo Combo for Colon Cancer Disappoints
6. New delivery method improves efficacy of 2 common Parkinsons disease medications
7. Sleep improves functioning in Parkinsons patients, but reasons remain elusive
8. PAP therapy improves depressive symptoms in all patients with sleep apnea
9. STeleR study: Telerehab improves functioning after stroke
10. Tiny implanted coil improves lung function in patients with severe emphysema
11. Study shows antibiotic improves respiratory function in lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of ... also new avenues for purchase. , The 2017 edition has wide jaws that will ... the older boomers as well as diabetics. This handle is reinforced for extra strength when ...
(Date:1/15/2017)... ... January 15, 2017 , ... San ... in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted and ... the award process. Results were announced the magazine’s January 2017 issue . ...
(Date:1/15/2017)... ... 2017 , ... The JPR Group, a public relations and ... will be assisting HackensackUMC Mountainside with its public relations efforts, effective January 2017. ... towns. The firm will be working closely with HackensackUMC Mountainside’s internal marketing operations. ...
(Date:1/14/2017)... ... , ... AgileMinder develops innovative products and services that bring "Care, Joy and ... Apple as a fun, free emoji sticker pack for iMessage. Use the stickers in ... coded values on The Emoji Scale. , On Apple: "The Emoji Scale by ...
(Date:1/13/2017)... Spain (PRWEB) , ... January 13, 2017 , ... The ... Melia Avenida America hotel on March 3-4, 2017. This Congress is expertly designed ... on the management of patients with lung cancer. , Chaired by Dr. Giorgio V. ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... synthetic Fentanyl arrived on the streets in 2015, dealers were ... samples, inviting would-be customers to test a newly-created batch. They ... The rapidly-growing demand for the powerful ... has racked up a staggering death toll across ... fentanyl sales reveals that they have sold nearly 400 grams ...
(Date:1/16/2017)... , January 16, 2017 According to the new ... Multi Display , Smart Display, Graphic LCD Controller), Application (Industrial Control, ... published by MarketsandMakets, the market is expected to grow from USD 17.26 ... CAGR of 9.68% between 2016 and 2022. ... ...
(Date:1/16/2017)... Colo. , Jan. 16, 2017  Northern Colorado,s ... is bringing advanced laser treatments to Loveland ... clinic focuses solely on the removal of unwanted tattoos ... fading for tattoo cover-ups. "Tattoos are beautiful ... the way we hope they would," said Johnny ...
Breaking Medicine Technology: